全文获取类型
收费全文 | 6675篇 |
免费 | 411篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 216篇 |
妇产科学 | 99篇 |
基础医学 | 719篇 |
口腔科学 | 163篇 |
临床医学 | 682篇 |
内科学 | 1356篇 |
皮肤病学 | 130篇 |
神经病学 | 629篇 |
特种医学 | 239篇 |
外科学 | 1310篇 |
综合类 | 60篇 |
一般理论 | 4篇 |
预防医学 | 453篇 |
眼科学 | 107篇 |
药学 | 459篇 |
中国医学 | 18篇 |
肿瘤学 | 356篇 |
出版年
2023年 | 33篇 |
2022年 | 62篇 |
2021年 | 170篇 |
2020年 | 103篇 |
2019年 | 173篇 |
2018年 | 170篇 |
2017年 | 134篇 |
2016年 | 154篇 |
2015年 | 193篇 |
2014年 | 233篇 |
2013年 | 343篇 |
2012年 | 483篇 |
2011年 | 537篇 |
2010年 | 307篇 |
2009年 | 236篇 |
2008年 | 424篇 |
2007年 | 488篇 |
2006年 | 426篇 |
2005年 | 393篇 |
2004年 | 352篇 |
2003年 | 330篇 |
2002年 | 318篇 |
2001年 | 108篇 |
2000年 | 78篇 |
1999年 | 66篇 |
1998年 | 70篇 |
1997年 | 51篇 |
1996年 | 41篇 |
1995年 | 30篇 |
1994年 | 33篇 |
1993年 | 30篇 |
1992年 | 50篇 |
1991年 | 32篇 |
1990年 | 44篇 |
1989年 | 35篇 |
1988年 | 32篇 |
1987年 | 39篇 |
1986年 | 27篇 |
1985年 | 24篇 |
1984年 | 41篇 |
1983年 | 24篇 |
1982年 | 20篇 |
1981年 | 14篇 |
1980年 | 14篇 |
1979年 | 20篇 |
1978年 | 18篇 |
1977年 | 11篇 |
1975年 | 8篇 |
1974年 | 9篇 |
1973年 | 9篇 |
排序方式: 共有7100条查询结果,搜索用时 15 毫秒
1.
2.
3.
A case of bullous pemphigoid associated with psoriasis vulgaris showing Hailey–Hailey disease‐like histopathological changes in regenerated epidermis without genomic mutation in ATP2C1 or ATP2A2 gene
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
4.
Hanna Lee Mary K. Tan Andrew T. Yan Paul Angaran Paul Dorian Claudia Bucci Jean C. Gregoire Alan D. Bell Martin S. Green Peter L. Gross Allan Skanes Charles R. Kerr L. Brent Mitchell Jafna L. Cox Vidal Essebag Brett Heilbron Krishnan Ramanathan Carl Fournier Shaun G. Goodman 《The Canadian journal of cardiology》2019,35(2):160-168
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献5.
Marie Ohata Susumu Fujiwara Ai Yoshioka Hiroshi Nagai Shintaro Sugita Nozomi Yamano Yusuke Inoue Chikako Nishigori 《Pediatric dermatology》2019,36(6):997-998
Fibroblastic connective tissue nevus (FCTN) is a benign cutaneous mesenchymal lesion characterized by proliferation of CD34‐positive fibroblastic/myofibroblastic spindle‐shaped cells. We report a case of agminated FCTN on the right lower abdomen of a 1‐year‐old boy. 相似文献
6.
7.
8.
The effect of oxitropium bromide (Ba253), a quaternary scopolamine derivative, on the resting tonus and agonist-induced contraction of isolated guinea pig airway smooth muscle and on the anaphylactic release of histamine and immunoreactive leukotrienes (i-LTs) from lung fragments were investigated and compared with those of Sch1000, atropine and isoproterenol. Ba253 dose-dependently inhibited the acetylcholine (ACh)-induced contraction of the isolated trachea and lung parenchyma. The degree of inhibitory potency was similar to that of Sch1000 and 10 times higher than that of atropine. Ba253 minimally influenced the resting tonus or contractions induced by other agonists including histamine, serotonin and LTD4. Sch1000 and atropine had similar or slightly stronger inhibitory effects on the tonus and contractions than Ba253. On the other hand, low concentrations of isoproterenol solely relaxed the resting tonus and inhibited the the agonist-induced contractions of both preparations. Neither Ba253 nor Sch1000 inhibited the anaphylactic release of histamine and LTs from both guinea pig and human lung fragments, but both mediator releases from either species were slightly inhibited with dose-dependency by atropine and potently inhibited by isoproterenol. From these results, it is suggested that Ba253 is a relatively specific antagonist to cholinergic receptors and might be possibly effective as an inhalant for asthma. 相似文献
9.
Amy Paul-Ward Gary Kielhofner Brent Braveman Mara Levin 《The American journal of occupational therapy》2005,59(5):540-545
The purpose of this study was to identify perceived barriers to independent community living and employment among clients and staff members in a transitional living facility for persons with AIDS. This qualitative study used focus groups to collect these perceptions from staff members (N = 21) and clients (N = 16). Whereas staff identified both systemic and personal barriers, clients only identified systemic barriers. These findings suggest that both clients and staff recognize the types of environmental barriers to participation that have been identified by disability scholars. The findings also underscore a consequential gap between clients' exclusive emphasis on environmental barriers and staff emphasis on clients' personal barriers that impact upon participation. 相似文献
10.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献